Setting International Standards in
Analysing Patient-Reported Outcomes
and Quality of Life Endpoints
Governance
SISAQOL-IMI is led by the EORTC and Boehringer Ingelheim.
The management structure of SISAQOL-IMI consists of the General Assembly, the Steering Committee, the Project Coordination team, Independent Ethics Advisory Board (IEAB) and the Independent Scientific Advisory Board (ISAB).
SISAQOL-IMI is a public-private collaborative research project:
| WP | Public Lead | EFPIA Lead |
|---|---|---|
| 1 | Andrew Bottomley, Madeline Pe, Ahu Alanya (EORTC) | Ingolf Griebsch (Boehringer Ingelheim) |
| 2 | Corneel Coens (EORTC) | Michael Schlichting (Merck KGaA) |
| 3 | Saskia le Cessie (Leiden University Medical Center) | Satrajit Roychoudhury (Pfizer) |
| 4 | Bernhard Holzner (Medical University of Innsbruck) | Jane Chang (Pfizer) |
| 5 | Martin Taphoorn (Leiden University Medical Center) | Paul Cislo (Pfizer) |
| 6 | Johannes Giesinger (Medical University of Innsbruck) | Jinma Ren (Pfizer) |
| 7 | Kristin Bjordal (Oslo University Hospital) | Vivek Pawar (EMD Serono) |
| 8 | Silene ten Seldam (Myeloma Patients Europe) | Elektra Papadopoulos (AbbVie) |